LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease
Pathogenic variants in LRPPRC disrupt mitochondrial gene expression, causing severe and incurable mitochondrial disease with neurological involvement accompanied by hepatopathy or cardiomyopathy. The development for gene therapy for LRPPRC-linked disease is hindered by the large LRPPRC coding sequence exceeding AAV cargo capacity when combined with classical regulatory elements. Here, we engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to heart and skeletal muscle-specific Lrpprc knockout mice. This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival. While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction. These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.